Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | June 30, 2026 | July 02, 2026 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Chief Medical Officer | September 15, 2023 | September 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,614 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Sale · Disposed 11,000 · Balance 162,614 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.915 to $5.9334 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.915 to $5.9334 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
PMV Pharmaceuticals, Inc.
Report date September 15, 2023 · Filed September 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,909 |
Reported balance
After 2023-09-15 transaction · row 1
1 source rowRow 1 · 2023-09-15 · Sale · Disposed 6,291 · Balance 45,909 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 11,000 | $5.92 | $65,087.00 |
DisclosureSEC source: 0001493152-26-031906 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,614 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.915 to $5.9334 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 18,065 | $5.09 | $91,961.69 |
DisclosureSEC source: 0001493152-26-004761 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,614 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003803 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,679 F1 · shares: All of the restricted stock will vest on January 26, 2027. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004748 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,366 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on January 31, 2026. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 23:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-034048 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,265 F1 · kind: The acquisition was exempt pursuant to Rule 16b-3(d). F2 · shares: This stock grant represents the remainder of the 2024 annual grant to board of directors. This portion of the annual stock grant was withheld until all employees/management were allocated their shares and in order to enable onboarding of two new Board members. All of the restricted stock will vest on August 26, 2025. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 23,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026643 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,468 F1 · shares: All of the restricted stock will vest on July 8, 2025. Read SEC document |
| May 16, 2024 Filed May 20, 2024 12:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon Stock | 11,000 | $4.71 | $51,799.00 |
DisclosureSEC source: 0001493152-24-020542 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,857 Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 7,246 | $3.90 | $28,269.54 |
DisclosureSEC source: 0001493152-23-034854 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,857 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8200 to $4.2000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 20:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 6,291 | $6.62 | $41,646.42 |
DisclosureSEC source: 0001209191-23-049751 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,909 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 58,689 | $4.62 | $271,143.18 |
DisclosureSEC source: 0001493152-23-021651 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,103 F1 · shares: All of the restricted stock will vest on June 14, 2024. Read SEC document |
| May 12, 2023 Filed May 15, 2023 22:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-029609 · doc4.xml · derivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-12 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:39 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027052 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,414 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:23 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantCommon Stock | 52,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-049692 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,200 F1 · shares: The reported shares are represented by restricted stock units, or RSUS. One- third of the RSUs vest on September 9, 2023 and the remaining shares vest on September 9, 2024. Read SEC document |
| February 10, 2022 Filed Feb 28, 2022 21:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 104,400 | $0.00 Strike: $16.29 | $0.00 |
DisclosureSEC source: 0001209191-22-013569 · doc4.xml · derivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,400 Underlying: Common Stock · 104,400 shares Expires 2032-02-10 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-055438 · doc4.xml · derivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,850 Underlying: Common Stock · 100 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 100 | $30.25 | $3,025.00 |
DisclosureSEC source: 0001209191-21-055438 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 100 | $3.90 | $390.00 |
DisclosureSEC source: 0001209191-21-055438 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 20:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-055140 · doc4.xml · derivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,950 Underlying: Common Stock · 3,900 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 20:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,900 | $30.25 | $117,975.00 |
DisclosureSEC source: 0001209191-21-055140 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 20:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 3,900 | $3.90 | $15,210.00 |
DisclosureSEC source: 0001209191-21-055140 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-050670 · doc4.xml · derivative · entry 5 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,850 Underlying: Common Stock · 4,000 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 224 | $36.69 | $8,218.56 |
DisclosureSEC source: 0001209191-21-050670 · doc4.xml · nonDerivative · entry 4 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,049 | $32.66 | $66,913.58 |
DisclosureSEC source: 0001209191-21-050670 · doc4.xml · nonDerivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.605 to $36.50, inclusive. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.605 to $36.50, inclusive. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,198 | $35.06 | $77,070.01 |
DisclosureSEC source: 0001209191-21-050670 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,802 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.575 to $35.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.575 to $35.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:14 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,000 | $3.90 | $15,600.00 |
DisclosureSEC source: 0001209191-21-050670 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:10 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-045989 · doc4.xml · derivative · entry 4 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,850 Underlying: Common Stock · 4,000 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:10 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,049 | $32.66 | $66,913.58 |
DisclosureSEC source: 0001209191-21-045989 · doc4.xml · nonDerivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.455 to $32.835, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:10 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,951 | $31.93 | $62,299.53 |
DisclosureSEC source: 0001209191-21-045989 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,049 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.455 to $32.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:10 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,000 | $3.90 | $15,600.00 |
DisclosureSEC source: 0001209191-21-045989 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 23:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-039035 · doc4.xml · derivative · entry 5 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,850 Underlying: Common Stock · 4,000 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 23:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,367 | $34.00 | $46,483.60 |
DisclosureSEC source: 0001209191-21-039035 · doc4.xml · nonDerivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.705 to $34.255, inclusive. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 23:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,633 | $33.39 | $87,903.23 |
DisclosureSEC source: 0001209191-21-039035 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.705 to $33.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 23:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,000 | $3.90 | $15,600.00 |
DisclosureSEC source: 0001209191-21-039035 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:41 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 98,168 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-21-013114 · ownership.xml · derivative · entry 2 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,168 Underlying: Common Stock · 98,168 shares Expires 2031-05-25 F2 · derivative.exercise_date: All of the stock options will vest on November 25, 2021. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:41 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 77,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013114 · ownership.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,181 F1 · shares: All of the restricted stock will vest on November 25, 2021. Read SEC document |
| May 12, 2021 Filed Jun 8, 2021 23:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 36,279 | $0.00 Strike: $28.33 | $0.00 |
DisclosureSEC source: 0001209191-21-039035 · doc4.xml · derivative · entry 4 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,279 Underlying: Common Stock · 36,279 shares Expires 2031-05-11 F4 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:06 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-031300 · doc4.xml · derivative · entry 4 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,850 Underlying: Common Stock · 4,000 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:06 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 158 | $35.49 | $5,607.28 |
DisclosureSEC source: 0001209191-21-031300 · doc4.xml · nonDerivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.47 to $35.50, inclusive. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:06 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,842 | $34.80 | $133,701.60 |
DisclosureSEC source: 0001209191-21-031300 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:06 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,000 | $3.90 | $15,600.00 |
DisclosureSEC source: 0001209191-21-031300 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001209191-21-026064 · doc4.xml · derivative · entry 4 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,850 Underlying: Common Stock · 4,000 shares Expires 2030-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 28 | $34.42 | $963.79 |
DisclosureSEC source: 0001209191-21-026064 · doc4.xml · nonDerivative · entry 3 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.37 to $34.50, inclusive. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,972 | $33.86 | $134,480.80 |
DisclosureSEC source: 0001209191-21-026064 · doc4.xml · nonDerivative · entry 2 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,000 | $3.90 | $15,600.00 |
DisclosureSEC source: 0001209191-21-026064 · doc4.xml · nonDerivative · entry 1 Alland Leila · CIK 0001825216 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.